Spondyloarthritis & psoriatic arthritis
Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions
Authors' conclusion
In this real-world study, TOF showed a reasonably good retention rate in a PsA population that was mostly refractory to biologic and oral targeted synthetic disease-modifying antirheumatic drugs. There were no new causes for concern regarding safety.
Study context
- Population
- All patients with psoriatic arthritis (PsA) who received at least 1 dose of tofacitinib (TOF), single centre; mean age 51.9 years; TOF ≥ third line in > 70%54 women and 18 men
- Participants
- 72 patients
- Outcome
- AEs and drug survival
Methodological detailssingle-centre, longitudinal observational, Kaplan-Meier, multivariate Cox regression
- Single-centre
- Longitudinal observational
- Kaplan-Meier
- Multivariate Cox regression
Main finding
As reported in the abstract
TOF drug survival
Median survival, months (IQR 5.3-29.0)
13.0
One-year retention rate
52.7%
95% CI 42.4–65.6
Observational data: associations, not effects.
Further findings
| Outcome | HR | P value |
|---|---|---|
| Drug discontinuation, younger ageLower odds of discontinuation | 0.96 | P = 0.01 |
| Drug discontinuation, enthesitisLower odds of discontinuation | 0.37 | P = 0.03 |
Safety
Overall rate of adverse events (AEs)
- AEs per 100 person-years
- 52.9 (95% CI 38.5-70.6)
- Most AEs occurred during the first 6 months of exposure
Original publication
Patients With Psoriatic Arthritis–Related Enthesitis and Persistence on Tofacitinib Under Real-World Conditions. J Rheumatol. Published 1 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →